UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 200 shares, a decline of 80.0% from the November 30th total of 1,000 shares. Based on an average daily volume of 11,900 shares, the days-to-cover ratio is currently 0.0 days.

UCB Stock Up -1.0 %

OTCMKTS UCBJY traded up $1.67 during mid-day trading on Thursday, hitting $99.02. The stock had a trading volume of 4,786 shares, compared to its average volume of 17,454. The firm’s 50 day moving average is $95.86 and its 200 day moving average is $88.13. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a twelve month low of $42.54 and a twelve month high of $100.01.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.